Eliana Merle
Stock Analyst at UBS
(2.25)
# 2,645
Out of 4,876 analysts
84
Total ratings
40.32%
Success rate
-0.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Downgrades: Neutral | $12 → $5.5 | $5.36 | +2.61% | 3 | Jun 26, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $16 → $8 | $9.19 | -12.94% | 3 | May 22, 2025 | |
| ARVN Arvinas | Maintains: Buy | $74 → $21 | $7.82 | +168.54% | 4 | May 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $72 → $70 | $44.69 | +56.63% | 3 | May 13, 2025 | |
| MRNA Moderna | Maintains: Buy | $78 → $70 | $27.29 | +156.50% | 7 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $441 → $458 | $302.71 | +51.30% | 4 | May 2, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $65 → $72 | $45.28 | +59.01% | 3 | Apr 30, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Overweight | $44 | $18.05 | +143.77% | 8 | Apr 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $54.72 | +106.51% | 2 | Feb 20, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $9.89 | +284.23% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $56.54 | +92.78% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.27 | +73.23% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $37.69 | +88.38% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $196 | $174.71 | +12.19% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $9.48 | +195.36% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $8.04 | +49.25% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $3.05 | -1.69% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $3.62 | +618.23% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $22.92 | +43.98% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $106.63 | +22.85% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $320.84 | -10.24% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $3.77 | +32.80% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $3.86 | +366.32% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $14.19 | +196.09% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $1.24 | +545.16% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.63 | +375.16% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.62 | +445.24% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.86 | +173.27% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $27.99 | +378.74% | 3 | Aug 19, 2020 |
CureVac
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.36
Upside: +2.61%
RAPT Therapeutics
May 22, 2025
Maintains: Neutral
Price Target: $16 → $8
Current: $9.19
Upside: -12.94%
Arvinas
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $7.82
Upside: +168.54%
Kymera Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $44.69
Upside: +56.63%
Moderna
May 2, 2025
Maintains: Buy
Price Target: $78 → $70
Current: $27.29
Upside: +156.50%
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $441 → $458
Current: $302.71
Upside: +51.30%
BridgeBio Pharma
Apr 30, 2025
Maintains: Buy
Price Target: $65 → $72
Current: $45.28
Upside: +59.01%
Apellis Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $18.05
Upside: +143.77%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $54.72
Upside: +106.51%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $9.89
Upside: +284.23%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $56.54
Upside: +92.78%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.27
Upside: +73.23%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $37.69
Upside: +88.38%
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $174.71
Upside: +12.19%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $9.48
Upside: +195.36%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $8.04
Upside: +49.25%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $3.05
Upside: -1.69%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $3.62
Upside: +618.23%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $22.92
Upside: +43.98%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $106.63
Upside: +22.85%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $320.84
Upside: -10.24%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.77
Upside: +32.80%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $3.86
Upside: +366.32%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $14.19
Upside: +196.09%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.24
Upside: +545.16%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $4.63
Upside: +375.16%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.62
Upside: +445.24%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $5.86
Upside: +173.27%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $27.99
Upside: +378.74%